Lack of iNOS impairs endothelial function in endothelin-1 transgenic mice

Kidney and Blood Pressure Research

Volumn 31, Issue 2, 2008, Pages 127-134

  Quaschning, Thomas ^a   Voss, Florian ^b,c   Herzfeld, Sophia ^c   Relle, Katharina ^c,d   Kalk, Philipp ^c,d   Godes, Michael ^c   Pfab, Thiemo ^c,d   Kraemer Guth, Annette ^a   Bonz, Andreas W ^b   Theuring, Franz ^c   Galle, Jan ^b   Hocher, Berthold ^c,e  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Endothelin; Endothelium; Endothelium dependent relaxation; Nitric oxide; Relaxation; Vasculature; Vasoconstriction

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HYPERTENSION; MALE; MOUSE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VASCULAR RING; WILD TYPE;

ANIMALS; AORTA; BLOOD PRESSURE; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II;

EID: 43049148372     PISSN: 14204096     EISSN: None     Source Type: Journal    
DOI: 10.1159/000124285     Document Type: Article

References (47)

1. 2+ channels. J Hypertens 1988;6(suppl):S188-S191.
2. Hirata Y, Takagi Y, Fukuda Y, Marumo F: Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989;78:225-228.
3. Takase H, Moreau P, Lüscher TF: Endothelin receptor subtypes in small arteries. Studies with FR139317 and bosentan. Hypertension 1995;25:739-743.
4. Hirata Y, Emori T, Eguchi S, Kanno K, Imai T, Ohta K, Marumo F: Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993;91:1367-1373.
5. B receptors in rats. Biochem Biophys Res Commun 1994;199:1461-1465.
6. B-mediated regulation of extracellular levels of endothelin-1 in cultured human endothelial cells. Biochem Biophys Res Commun 1995;209:483-489.
7. B receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation 1995;92:357-363.
8. Boulanger C, Lüscher TF: Release of endothelin from the porcine aorta. Inhibition by endothelium-derived nitric oxide. J Clin Invest 1990;85:587-590.
9. Stewart DJ, Cernacek P, Mohamed F, Blais D, Cianflone K, Monge JC: Role of cyclic nucleotides in the regulation of endothelin-1 production by human endothelial cells. Am J Physiol 1994;266:H944-H951.
10. Slowinski T, Kalk P, Christian M, Schmager F, Relle K, Godes M, Funke-Kaiser H, Neumayer HH, Bauer C, Theuring F, Hocher B: Cell-type-specific interaction of endothelin-and nitric oxide system - pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice. J Physiol 2007;581:1173-1181.
11. Lüscher TF, Richard V, Tschudi M, Yang ZH, Boulanger C: Endothelial control of vascular tone in large and small coronary arteries. J Am Coll Cardiol 1990;15:519-527.
12. Schiffrin EL, Lariviere R, Li JS, Sventek P, Touyz RM: Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension 1995;25:769-773.
13. Hocher B, George I, Rebstock J, Bauch A, Schwarz A, Neumayer HH, Bauer C: Endothelin system-dependent cardiac remodeling in renovascular hypertension. Hypertension 1999;33:816-822.
14. Ruschitzka F, Quaschning T, Noll G, deGottardi A, Rossier MF, Enseleit F, Hürlimann D, Lüscher TF, Shaw SG: Endothelin-1 type a receptor antagonism prevents vascular dysfunction and hypertension induced by 11β-hydroxysteroid dehydrogenase inhibition: role of nitric oxide. Circulation 2001;103:3129-3135.
15. Black HR, Bakris GL, Weber MA, Weiss R, Shahawy ME, Marple R, Tannoury G, Linas S, Wiens BL, Linseman JV, Roden R, Gerber MJ: Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007;9:760-769.
16. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, Siegmund F, Quertermous T, Bauer C, Neumayer HH, Schleuning WD, Theuring F: Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-1389.
17. Shindo T, Kurihara H, Maemura K, Kurihara Y, Ueda O, Suzuki H, Kuwaki T, Ju KH, Wang Y, Ebihara A, Nishimatsu H, Moriyama N, Fukuda M, Akimoto Y, Hirano H, Morita H, Kumada M, Yazaki Y, Nagai R, Kimura K: Renal damage and salt-dependent hypertension in aged transgenic mice overexpressing endothelin-1. J Mol Med 2002;80:105-116.
18. Liefeldt L, Schonfelder G, Bocker W, Hocher B, Talsness CE, Rettig R, Paul M: Transgenic rats expressing the human ET-2 gene: a model for the study of endothelin actions in vivo. J Mol Med 1999;77:565-574.
19. Hocher B, Liefeldt L, Thone-Reineke C, Orzechowski HD, Distler A, Bauer, C, Paul M: Characterization of the renal phenotype of transgenic rats expressing the human endothelin-2 gene. Hypertension 1996;28:196-201.
20. Lüscher TF, Yang Z, Tschudi M, von Segesser L, Stulz P, Boulanger C, Siebenmann R, Turina M, Buhler FR: Interaction between endothelin-1 and endothelium-derived relaxing factor in human arteries and veins. Circ Res 1990;66:1088-1094.
21. A receptor-mediated generation of hydrogen peroxide. Am J Physiol 2005;288:L480-L487.
22. Gonon AT, Erbas D, Broijersen A, Valen G, Pernow J: Nitric oxide mediates protective effect of endothelin receptor antagonism during myocardial ischemia and reperfusion. Am J Physiol 2004;286:H1767-H1774.
23. Quaschning T, Kocak S, Bauer C, Neumayer HH, Galle J, Hocher B: Increase in nitric oxide bioavailability improves endothelial function in endothelin-1 transgenic mice. Nephrol Dial Transplant 2003;18:479-483.
24. Patzak A, Bontscho J, Lai E, Kupsch E, Skalweit A, Richter CM, Zimmermann M, Thone-Reineke C, Joehren O, Godes M, Steege A, Hocher B: Angiotensin II sensitivity of afferent glomerular arterioles in endothelin-1 transgenic mice. Nephrol Dial Transplant 2005;20:2681-2689.
25. Hocher B, Schwarz A, Slowinski T, Bachmann S, Pfeilschifter J, Neumayer HH, Bauer C: In-vivo interaction of nitric oxide and endothelin. J Hypertens 2004;22:111-119.
26. Quaschning T, Voss F, Relle K, Kalk P, Vignon-Zellweger N, Pfab T, Bauer C, Theilig F, Bachmann S, Kraemer-Guth A, Wanner C, Theuring F, Galle J, Hocher B: Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol 2007;18:730-740.
27. Asakura H, Asamura R, Ontachi Y, Hayashi T, Yamazaki M, Morishita E, Miyamoto KI, Nakao S: Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats. J Thromb Haemost 2005;3:1050-1055.
28. Shimojo N, Jesmin S, Zaedi S, Soma M, Kobayashi T, Maeda S, Yamaguchi I, Goto K, Miyauchi T: EPA effect on NOS gene expression and on NO level in endothelin-1-induced hypertrophied cardiomyocytes. Exp Biol Med (Maywood) 2006;231:913-918.
29. Hocher B, Schwarz A, Fagan KA, Thone-Reineke C, El Hag K, Kusserow H, Elitok S, Bauer C, Neumayer HH, Rodman DM, Theuring F: Pulmonary fibrosis and chronic lung inflammation in ET-1 transgenic mice. Am J Respir Cell Mol Biol 2000;23:19-26.
30. Quaschning T, Ruschitzka F, Stallmach T, Shaw S, Morawietz H, Goettsch W, Hermann M, Slowinski T, Theuring F, Hocher B, Luscher TF, Gassmann M: Erythropoietin-induced excessive erythrocytosis activates the tissue endothelin system in mice. FASEB J 2003;17:259-261.
31. Quaschning T, d'Uscio LV, Shaw S, Lüscher TF: Vasopeptidase inhibition exhibits endothelial protection in salt- induced hypertension. Hypertension 2001;37:1108-1113.
32. A receptor blockade prevents increased tissue endothelin-1, vascular hypertrophy, and endothelial dysfunction in salt-sensitive hypertension. Hypertension 1998;31:499-504.
33. 3. J Hypertens 2005;23:1067-1075.
34. Turner NC, Power RF, Polak JM, Bloom SR, Dollery CT: Endothelin-induced contractions of tracheal smooth muscle and identification of specific endothelin binding sites in the trachea of the rat. Br J Pharmacol 1989;98:361-366.
35. Marsault R, Vigne P, Breittmayer JP, Frelin C: Kinetics of vasoconstrictor action of endothelins. Am J Physiol 1991;261:C987-C993.
36. Hocher B, Rohmeiss P, Diekmann F, Zart R, Vogt V, Schiller S, Bauer C, Koppenhagen K, Distler A, Gretz N: Distribution of endothelin receptor subtypes in the rat kidney. Renal and haemodynamic effects of the mixed (A/B) endothelin receptor antagonist bosentan. Eur J Clin Chem Clin Biochem 1995;33:463-472.
37. 2+ signals induced by endothelin-1 in a human bronchial epithelial cell line. Cell Calcium 1997;21:221-231.
38. A receptors in airway epithelial cells. Naunyn Schmiedebergs Arch Pharmacol 2000;361:120-126.
39. Rossi GP, Seccia TM, Nussdorfer GG: Reciprocal regulation of endothelin-1 and nitric oxide: relevance in the physiology and pathology of the cardiovascular system. Int Rev Cytol 2001;209:241-272.
40. Keller S, Karaa A, Paxian M, Clemens MG, Zhang JX: Inhibition of endothelin-1-mediated up-regulation of iNOS by bosentan ameliorates endotoxin-induced liver injury in cirrhosis. Shock 2006;25:306-313.
41. Shimojo N, Jesmin S, Zaedi S, Soma M, Kobayashi T, Maeda S, Yamaguchi I, Goto K, Miyauchi T: EPA effect on NOS gene expression and on NO level in endothelin-1-induced hypertrophied cardiomyocytes. Exp Biol Med (Maywood) 2006;231:913-918.
42. Ramzy D, Rao V, Tumiati LC, Xu N, Sheshgiri R, Miriuka S, Delgado DH, Ross HJ: Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation 2006;114:I319-I326.
43. Schiffrin EL: State-of-the-art lecture. Role of endothelin-1 in hypertension. Hypertension 1999;34:876-881.
44. A-selective endothelin receptor antagonism on blood pressure in experimental and genetic hypertension in rats. Br J Pharmacol 1997;121:935-940.
45. Quaschning T, Ruschitzka F, Niggli B, Lunt CM, Shaw S, Christ M, Wehling M, Lüscher TF: Influence of aldosterone vs. endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dial Transplant 2001;16:2146-2151.
46. Ergul A: Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension 2000;36:62-67.
47. Slowinski T, Neumayer HH, Stolze T, Gossing G, Halle H, Hocher B: Endothelin system in normal and hypertensive pregnancy. Clin Sci (Lond) 2002;103(suppl 48):446S-449S.